FDA puts two Intellia CRISPR trials on hold following liver toxicity case

The FDA suspended two of Intellia Therapeutics’ clinical trials of a gene editing treatment for transthyretin amyloidosis, or ATTR, a disease in which misfolded proteins build up in the heart or nerves and cause damage ...